Forecast & RatingOnly 1 analyst currently covers TransCode Therapeutics (RNAZ.US), with a price target of $280.00 and a rating of "Overweight". The sample is very small, so treat this as a reference only. Data as of Jan 6, 2026; this does not constitute investment advice.
Apr 16, 2025Price forecast
$280.009829.07%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateApr 27, 2025
Forecast met0.0%
Stock price$14.34
Avg. target$280.0
High target$280
Low target$280
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.